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1. Introduction  
Intestinal carcinogenesis is the final outcome of a multi-step process resulting from genetic 
alterations that are influenced by two categories of factors: environmental factors and host-
related factors such as cytokines and hormones (including sex steroid hormones).  One of 
the most important environmental factors involved in the development of colon cancer is 
dietary components. However, variations in cancer incidence among and within 
populations with similar dietary patterns suggest that the predominant pathogenetic factor 
is the individual response, through the expression of different protein and metabolite 
patterns (1).  Among host-related factors particular attention is paid in this work to  the 
relationship between estrogens, as well as their agonists (phytoestrogens), and colon cancer, 
and the possible role of these latter substances in the prevention of colon cancer.  
2. APC gene in colorectal cancer 
Colorectal cancer (CRC) is the final outcome of a multi-step process that, in most cases, 
proceeds down  the adenoma–carcinoma sequence pathway (2). 
The tumor suppressor gene mutation involving the Adenomatous Polyposis Coli (APC) gene is 
present  in 80% of  sporadic CRCs and  100% of cases of Familial Adenomatous Polyposis 
(FAP). In humans, the APC mutation provides the genetic background to the onset of the 
tumor process, making intestinal cells susceptible to tumor progression and promotion 
through the accumulation of further mutations as a result of epigenetic phenomena largely 
influenced by environmental factors (3).  
FAP offers  an ideal model for the study of CRC since in these patients “normal” mucosa 
coexists with low and high-grade dysplastic lesions as well adenocarcinoma, i.e. all the 
stages of the carcinogenetic process.  For this reason  the modifications occurring during the 
carcinogenetic process are easily comparable and free from individual variations (4).  
3. Estrogens in colorectal cancer 
Phytoestrogens (heterocyclic non steroid phenols) are plant-derived compounds with a 
structural and functional action as estrogen agonists in mammals. To understand their 
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biological activities and the possible interactions between phytoestrogens and colorectal 
cancer, a knowledge of some fundamental data on estrogens is essential.  
Estrogen biological activities are mainly mediated by their binding with two specific 
receptors: estrogen receptor alpha (ER-┙) and estrogen receptor beta (ER-┚). Both of these 
estrogen receptors (ERs) belong to the steroid/thyroid hormone receptor superfamily of 
nuclear receptors, which are activated upon binding of the ligand. After binding, activated 
ERs are able to interact directly with cis-regulatory elements of target genes by binding to 
estrogen-response elements (EREs), or indirectly through interaction with another DNA-
bound transcription factor, such as activator protein 1 (AP-1), thus facilitating the assembly 
of basal transcription factors into a stable pre-initiation complex, followed by increased 
transcription rates for target mRNAs (5). 
Both ERs consist of three main regions: 1) a hypervariable N-terminal, that contributes to the 
transactivation function, 2) a highly conserved DNA-binding domain, responsible for 
specific DNA-binding and dimerization and 3) a C-terminal domain, involved in ligand-
binding (LBD) and nuclear localization, as well as ligand-dependent transactivation 
functions. ER-┙ and ER-┚ are produced by different genes located on different chromosomes 
(6).  
In mammals, both ER-┙ and ER-┚ have conserved DNA binding domains (96%) but they 
have different LBD showing only 58% homology. ER-┙ has two distinct transcriptional 
activation functions (AF): AF-1 and AF-2. AF-1, located at the N-terminal, is ligand-
independent, constitutively active and contributes to the transcriptional activity of the 
receptor by recruiting co-activator proteins such as GRIP1 and SRC-1 and the histone 
acetyltransferases (HAT) p300/CBP and pCAF. The AF-2 domain is under the control of 
ligands in both ER-┙ and ER-┚. 
Variations observed in the phenotypes of knock-out mice lacking ER-┙ or ER-┚ suggest that 
these two proteins have different biological activities. This view has been further supported 
by in vitro and in vivo studies in ER-┚ knock-out mice, indicating that ER-┚ is a modulator 
of ER-┙ activity as it is able to reverse the effects of ER-┙ and to inhibit estradiol (E2)-
dependent proliferation (7). In addition, it is known that ER-┙ and ER-┚ have a different 
distribution in the various organs and apparatuses. ER-┙ is essentially expressed in the 
breast, bone, cardiovascular tissue, urogenital tract and central nervous system, while ER-┚ 
is the prevalent form in the gut. Both receptors bind E2 but they activate promoters in 
different ways. Studies on breast and prostate carcinogenesis suggest an opposite role of ER-
┙ and ER-┚ in the proliferation and differentiation of target tissues, a hypothesis described 
as the ying/yang relationship (8).   
Estrogens regulate cellular function also through non-genomic pathways. In fact, after 
palmitoylation ERs can localize at the plasma membrane, associate to caveolin-1 and, upon 
estrogens stimulation, activate rapid signals. In the case of ER-┙, palmitoylation stimulates 
proliferation, while ER-┚ localization at the plasma membrane and its association with 
caveolin-1 activates p38 (a member of the MAPK family), that promotes apoptosis (9). This 
finding is confirmed by the observation, in the tumor tissue, of a reduction of ER-┚ and an 
increased alpha/beta ratio, that is related to a reduction of apoptosis and an increased rate 
of proliferation. 
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In the last few years, numerous epidemiological, clinical and experimental studies have 
explored the role of estrogens in intestinal carcinogenesis, suggesting their protective role 
and potential use in CRC prevention (10-14). In particular, estrogen protective activities are 
thought to be related to their receptor subtype beta (ER-┚), suggesting the use of selective 
ER-┚ agonists in primary CRC prevention . 
Since the early 80s, the role of a progressive silencing of Estrogen Receptor beta (ER┚) 
expression in intestinal cells, as a pathogenetic factor involved in intestinal tumorigenesis 
and its progression to an overt cancerous phenotype, has been studied in both animal 
models and clinical settings (11-14).  
There is some evidence supporting ER-┚ as a prognostic factor in sporadic adenocarcinoma, 
and suggesting its role as a relevant surrogate biomarker in the follow-up of intestinal 
neoplasia development and dysplastic severity (15-18).  
In the ApcMin/+ mouse, that represents the animal model equivalent to FAP in humans, the 
loss of apoptotic control also occurs in non adenomatous (normal) mucosa, again depending 
upon a decreased ER-┚ expression and related decreased TUNEL and caspase-3 expression. 
In intact male ApcMin/+ mice it has been demonstrated that supplementing the diet with 
selected, weak but specific ER-┚ agonists reversed the hyperproliferative behavior in non 
adenomatous mucosa, and reduced the number and the degree of polyp dysplasia in 
adenomatous mucosa (19). 
In human sporadic polyps, a progressive, significant decrease of ER-┚ expression has been 
demonstrated, a finding confirmed in subjects affected by Familial Adenomatous Polyposis 
(FAP) (4).  In these patients, in fact, a progressive, significant decrease of ER-┚ expression 
was observed in the different stages of the disease, correlated with apoptosis (r=0.76, p< 
0.001), and inversely correlated with cell proliferation.  
4. Phytoestrogens and CRC 
Phytoestrogens are heterocyclic, non steroid phenols extracted from plants. These 
compounds are structurally similar and have a functional action as estrogen-agonists in 
mammals. Four classes of phytoestrogens can be distinguished, on the basis of their 
different molecular structure and different biological activities, namely isoflavones, lignans, 
coumestans and lactones (20-21). 
Isoflavones, including genistein and quercitin, are the most known phytoestrogens. They 
are primarily found in the Fabaceae family, which includes legumes, soybean, peanut and 
clover.  
Lignans were first identified in plants and later in biological fluids of mammals. These 
compounds are found in whole grain, seeds, fruits and vegetables but also in beverages 
such as coffee and tea (22). The cyclic urinary excretion of these phenolic compounds during 
the menstrual cycle led to investigations of their biological role, and they are now 
considered as a new hormone class (23). 
Coumestans are less common in the human diet than isoflavones; they are extracted from 
fodder, clover, legumes and soybean.  
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Lactones are the least common phytoestrogens in the human diet.  
Natural phytoestrogens undergo glycosidic binding to carbohydrates to produce complex 
molecules that are hard for the intestinal tract to absorb. For this reason, after ingestion, this 
glycosidic binding is broken up by glycosidases, enzymes produced by intestinal microflora. 
This enzymatic digestion generates ‘‘aglycone’’, a compound that is quickly absorbed and 
can bind ERs (24).   
Phytoestrogens are characterized by a higher binding affinity to ER-┚ as compared to the 
other estrogen receptor subtype, alpha (ER-┙). This biological characteristic explains why 
the administration of phytoestrogens does not produce the classic side effects associated to 
estrogen administration (cerebro- and cardiovascular attacks, a higher incidence of 
endometrial and breast cancer) (25-27), making these substances ideal candidates for CRC 
prevention.  
As proposed for estrogens, genomic and non-genomic mechanisms have been also 
suggested for phytoestrogens to explain their biological activities (20; 28-32). 
One of the most interesting compounds is Silymarin, initially extracted from Silybum 
marianum. It is a mixture of four flavolignans (silibinin, isosilibinin, silydianin and 
silychristin) and the isoflavone taxifolin. It is already used in the treatment of alcoholic liver 
disease and as an anti-fibrotic agent (33). 
Extensive research within the last decade has shown that silymarin can suppress the 
proliferation of a variety of tumor cells (e.g., prostate, breast, ovary, colon, lung, bladder); 
this is accomplished through cell cycle arrest at the G1/S-phase, induction of cyclin-
dependent kinase inhibitors (such as p15, p21 and p27), down-regulation of anti-apoptotic 
gene products (e.g., Bcl-2 and Bcl-xL), inhibition of cell-survival kinases (AKT, PKC and 
MAPK) and inhibition of inflammatory transcription factors (e.g., NF-kappaB). Silymarin 
can also down-regulate gene products involved in the proliferation of tumor cells (cyclin D1, 
EGFR, COX-2, TGF-beta, IGF-IR), invasion (MMP-9), angiogenesis (VEGF) and metastasis 
(adhesion molecules). The antiinflammatory effects of silymarin are mediated through 
suppression of NF-kappaB-regulated gene products, including COX-2, LOX, inducible 
iNOS, TNF and IL-1 (35). 
Silymarin has also been shown to sensitize tumors to chemotherapeutic agents through 
down-regulation of the MDR protein and other mechanisms. It binds to both estrogen and 
androgen receptors, and down-regulates PSA. In addition to its chemopreventive effects, 
silymarin exhibits antitumor activity against human tumors (e.g., prostate and ovary) in 
rodents (35) 
Seidlova-Wuttke et al. (34) have demonstrated the selective binding of silymarin to ER-┚ 
and no binding to ER-┙, but, how mentioned above, beyond its specific ER-┚ agonism 
silymarin, exerts an anti 5-lipoxygenase (LOX) and anti-COX2 effect (35-36).  
There is strong positive correlation has been recently established between 5-LOX 
overexpression and the appearance of typical high-risk factors for malignant transformation 
of polyps, such as histological epithelial localization, increased polyp size, villous and 
tubulovillous adenomas, high grade of intraepithelial neoplasia, and patient age because 
both inflammatory enzymes are up-regulated in colon carcinogenesis and involved in 
silencing apoptosis (37). 
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Finally have been demonstrated that, without any apparent toxicity, the feeding of 
polyphenols from silymarin suppressed the tumor growth of the human SW480 CRC, 
implanted in nu/nu mice. The inhibitory activity was associated with strong anti-
proliferative (┚-catenin, c-Myc and cyclin D1 suppression) and pro-apoptotic effects. (36).   
Even lignans exert similar activity in several human cancers. For example Touillaud et al. 
examined associations between the risk of postmenopausal invasive breast cancer and 
dietary intakes of four plant lignans (pinoresinol, lariciresinol, secoisolariciresinol, and 
matairesinol) and estimated exposure to two enterolignans (enterodiol and enterolactone), 
as measured with a self-administered diet history questionnaire, among postmenopausal 
French women who were not taking soy isoflavone supplements. They demonstrate that 
high dietary intakes of plant lignans and high exposure to enterolignans were associated 
with reduced risks of Estrogen receptor negative and Progesteron receptor positive 
postmenopausal breast cancer in a Western population that does not consume a diet rich in 
soy (56). On the other hand Kuiisten et al. studied the associations between plasma 
enterolignans and the risk of colorectal adenomas in a Dutch case-control study . Colorectal 
adenomas are considered to be precursors of colorectal cancer. Cases with at least one 
histologically confirmed colorectal adenoma and controls with no history of any type of 
adenoma were included. Plasma enterodiol and enterolactone concentrations were 
measured by liquid chromatography with tandem mass spectrometry and they observed a 
substantial reduction in colorectal adenoma risk among subjects with high plasma 
concentrations of enterolignans, in particular, enterodiol (42). 
Lignans exert a similar activity in several human colon cancer cells and are easily 
metabolized and absorbed in the colon (38-41). Lignin is a documented absorbant of 
carcinogens in the intestinal lumen. Its degradation to enterolignans by human intestinal 
microbiota could delay lignan release (42). 
5. Phytoestrogens in experimental CRC  
Mice with the Apc gene (ApcMin/+) mutation are highly susceptible to spontaneous intestinal 
adenoma formation and  are therefore considered the most suitable model for experimental 
CRC studies (43). A recent experimental study demonstrated that in ovariectomized 
ApcMin/+ female mice, the administration of a diet enriched with the phytoestrogen 
cumestrol induced a reduction of the number of polyps and an increased enterocyte 
migration as compared to control animals. Cumestrol was chosen in this study because it is 
a potent ER-┚ agonist, with a 200-fold higher affinity  than estradiol (44). 
Seidlova-Wuttke et al. (34) compared the effect of silymarin and estradiol in ovariectomized 
female mice and confirmed the selective binding of silymarin to ER-┚ by in vitro 
experiments. In another study, conducted by Khono et al., a silymarin-enriched diet 
significantly reduced azoxymethane-induced intestinal carcinogenesis in male mice. This 
effect was dose-dependent and determined a reduction of the number of cryptic adenomas, 
that are known to precede the development of colic adenocarcinoma (45). 
The effect of a 0.02% silymarin-enriched diet on tumor development was also tested in intact 
ApcMin/+ male mice, i.e. in physiological conditions. Intestinal polyp development was 
evaluated together with ER-┚ expression, as well as other biological parameters influencing 
tumor growth (epithelial cell proliferation, apoptosis and migration), following the addition 
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of a combination of the ER-┚-selective agonist silymarin and/or lignin to a high-fat/low-
fiber diet, which has been shown to foster  tumor growth. The addition of silymarin or 
lignin to the diet and, to an even greater extent,  the specific combination of the two, 
significantly counteracted intestinal tumorigenesis and increased ER-┚ mRNA and protein 
levels. Cell proliferation and apoptosis were rebalanced and cell migration accelerated, 
restoring values similar to those observed in wild type animals. These results further 
support a protective effect of ER-┚ in CRC, suggesting that dietary supplementation with 
the combination of silymarin and lignin could be  a potential approach to  CRC prevention 
(46). 
6. Phytoestrogens in human CRC  
Several studies have reported a reduction of the CRC risk associated with the consumption 
of soy foods (the main source of isoflavones) and non-fermented soy foods (e.g. tofu) (47-
52). The main limitations of these studies are that they all assessed only specific soy foods 
intake rather than total phytoestrogen intake: none of the studies was designed to evaluate 
phytoestrogen intake. 
Another study investigated the association between colorectal cancer and lignans commonly 
present in Western diets. Dietary lignan intake produced a significant reduction in colorectal 
cancer risk (53). 
Few epidemiologic studies have been conducted on the relationship between 
phytoestrogens and colorectal polyps formation. A case-control study on the role of lignans 
(54) suggests that these compounds may be protective against cardiovascular diseases and 
polyps (55). 
Our research group aimed to assess whether a specifically ER┚-targeted dietary 
management of human, recurrent sporadic adenopolyposis could have any impact on ER┚-
controlled apoptosis and/or proliferative behavior. As a preliminary step, we  assessed 
whether  non adenomatous (normal) mucosa of patients affected by sporadic 
adenopolyposis displayed an impaired apoptotic control of cell proliferation, dependent 
upon a reduced ER-┚ expression similar to that observed  in the ApcMin/+ mouse. We 
designed a randomized, double blind placebo-controlled study to further assess whether a 
proprietary blend of ER-┚ agonists (a mixture of silymarin, 30% of which as silibinin) could 
positively affect the ER┚-dependent apoptotic control of cell proliferation, in the normal 
mucosa of patients affected by sporadic adenopolyposis, prone to polyp recurrence, and 
enrolled in a surveillance program for the follow-up of polyp recurrence by screening 
colonoscopy every 3-5 years.  
We also assessed urinary phytoestrogens to check  for compliance to sylimarin 
supplementation, and to see whether biomarkers expression was differently related to the 
phytoestrogens from the regular diet as opposed to the  supplements given during the study 
period, in the two study groups. All patients were instructed to maintain their regular diet 
over the study period. Urinary phytoestrogens (ng/mL), namely the active lignans: 
enterodiol (ED) and enterolactone (EL), were measured on spot urinary samples. 
In this clinical trial, we similarly hypothesized a ER┚ down-modulation, paving  the way for 
an altered apoptotic control of cell proliferation, in the non adenomatous colon mucosa of 
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patients affected by sporadic adenopolyposis,  presenting with a similar cell proliferation 
rate. We found  that the normal mucosa of an APC-mutated intestinal environment  is prone 
to polyp development and recurrence because of an altered proliferation-apoptosis  ratio, 
related to a decreased ER-┚ expression. Moreover, we demonstrated  that ER-┚ dependent 
apoptosis can be restored by administering specific phytoestrogens supplements with a 
selective action  on ER┚, in a similar manner to what we had  previously observed in  
ApcMin/+ mice. This randomized, double-blind placebo-controlled study showed that 
sylimarin, lignans and lignin can positively affect the ER┚-driven apoptotic control of colon 
epithelial turnover, by increasing ER-┚ expression in the normal mucosa of sporadic 
adenopolyposis patients prone to polyp recurrence.  This is achieved via an increased ER┚ 
content and was demonstrated in all patients, regardless of whether they were free from  
polyps or not,  at screening colonoscopy. 
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